Medication info
Jemimet Extended-Release Tablet 50/1000 mg

Jemimet Extended-Release Tablet 50/1000 mg

Prescription medicationTabletOral
Ingredient · strength
Gemigliptin Tartrate Sesquihydrate›68.9mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
LG Chem, Ltd.
Appearance
Brown oblong film-coated tablet
Packaging
30 tablets/bottle, 100 tablets/bottle, 56 tablets (14 tablets/PTP × 4)
Approval status
Active

MFDS item code 201405223 · Approved 2014.11.07 · Insurance code 668902910

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this drug should be individualized based on the patient's current treatment regimen, efficacy, and tolerability. This drug is generally administered with the evening meal, and the dose is increased gradually to reduce gastrointestinal adverse reactions associated with metformin. Take one 50/500mg extended-release tablet or one 50/1000mg extended-release tablet once daily. Patients taking 25/500mg extended-release tablets or 25/1000mg extended-release tablets should take 2 tablets together once daily. - For patients not currently receiving metformin who require gemigliptin 50mg, the recommended starting dose of this drug is one gemigliptin 50mg/metformin 500mg extended-release tablet once daily, with gradual dose escalation to reduce gastrointestinal adverse reactions to metformin. - In patients who do not achieve adequate glycemic control with metformin monotherapy, or with combination therapy of metformin and a sulfonylurea or metformin and insulin, the initial dose of this drug should provide gemigliptin 50 mg once daily and the patient's previous metformin dose. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately. - When this drug is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be necessary to reduce the risk of hypoglycemia. - In patients switching from combination therapy with gemigliptin and metformin to this drug, the dose may be started at the patient's previous doses of gemigliptin and metformin. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately. The maximum recommended daily dose is gemigliptin 50mg and extended-release metformin 2000mg. The safety and efficacy of this drug have not been specifically evaluated in patients switching from other antihyperglycemic agents. Because any change may cause a change in glycemic control, changes in the treatment of patients with type 2 diabetes should be made under close monitoring. This drug must be swallowed whole and must never be crushed, cut, or chewed.

Ingredients

Manufacturer
LG Chem, Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication helps patients with type 2 diabetes control their blood sugar more effectively when used alongside diet and exercise therapy. The combination of gemigliptin and metformin stabilizes blood sugar levels, providing significant assistance in diabetes management. Thus, it is suitable for those who find it difficult to manage blood sugar regularly, and consistent use is expected to yield positive effects in blood sugar control.

How to take

Adult dose

The dose of this drug should be individualized based on the patient's current treatment regimen, efficacy, and tolerability. This drug is generally administered with the evening meal, and the dose is increased gradually to reduce gastrointestinal adverse reactions associated with metformin. Take one 50/500mg extended-release tablet or one 50/1000mg extended-release tablet once daily. Patients taking 25/500mg extended-release tablets or 25/1000mg extended-release tablets should take 2 tablets together once daily. - For patients not currently receiving metformin who require gemigliptin 50mg, the recommended starting dose of this drug is one gemigliptin 50mg/metformin 500mg extended-release tablet once daily, with gradual dose escalation to reduce gastrointestinal adverse reactions to metformin. - In patients who do not achieve adequate glycemic control with metformin monotherapy, or with combination therapy of metformin and a sulfonylurea or metformin and insulin, the initial dose of this drug should provide gemigliptin 50 mg once daily and the patient's previous metformin dose. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately. - When this drug is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be necessary to reduce the risk of hypoglycemia. - In patients switching from combination therapy with gemigliptin and metformin to this drug, the dose may be started at the patient's previous doses of gemigliptin and metformin. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately. The maximum recommended daily dose is gemigliptin 50mg and extended-release metformin 2000mg. The safety and efficacy of this drug have not been specifically evaluated in patients switching from other antihyperglycemic agents. Because any change may cause a change in glycemic control, changes in the treatment of patients with type 2 diabetes should be made under close monitoring. This drug must be swallowed whole and must never be crushed, cut, or chewed.

Precautions

This medication can rarely cause a serious condition known as lactic acidosis. Lactic acidosis can pose a life-threatening risk due to excessive accumulation of acidic substances in the blood, so special caution is required during treatment with this medication. Additionally, hypoglycemia may occur when used in conjunction with other diabetes medications, such as insulin or sulfonylureas, so blood sugar levels should be closely monitored. This medication should not be used in specific patients, such as those with moderate to severe renal impairment, patients with heart failure, those who have suffered an acute myocardial infarction, patients with severe liver dysfunction, or women who are pregnant or breastfeeding. Before undergoing tests that use radioiodine contrast agents, this medication should be discontinued at least 48 hours prior, and it should only be resumed after confirming that renal function is normal. If symptoms of acute pancreatitis, such as severe abdominal pain, occur during treatment with this medication, it should be stopped immediately and medical consultation is required. Since blood levels of vitamin B12 may decrease, regular blood tests and appropriate treatment, if necessary, should be performed. Skin reactions such as bullous pemphigoid or severe hypersensitivity may occur; if any skin abnormalities arise, you must inform your doctor immediately. When administering this medication to the elderly, caution must be exercised regarding potential renal impairment, and regular renal function tests should be conducted. In case of overdose, seek medical attention promptly for appropriate treatment, especially if symptoms of lactic acidosis are suspected. This medication may interact with other drugs, so it is essential to inform your healthcare provider about any additional medications being taken. Also, the tablet coating may be excreted in the stool, but this does not affect the medication's efficacy, so there's no need for concern. Generally, excessive alcohol consumption should be avoided while taking this medication, and special caution is needed, particularly in cases of liver or kidney disease. Before undergoing any surgery or procedure, consult with your healthcare provider to determine whether to discontinue this medication.

Side effects

  • Severe lactic acidosis
  • severe hypoglycemia
  • arthralgia
  • nasopharyngitis
  • bacteriuria
  • upper respiratory infection
  • increased serum CPK levels
  • diarrhea
  • urinary tract infection
  • dizziness
Show 70 more
  • nausea
  • malaise
  • myalgia
  • headache
  • constipation
  • symptomatic hypoglycemia
  • symptomatic hyperglycemia
  • pharyngitis
  • increased serum amylase levels
  • increased lipase levels
  • fever
  • hypoglycemic syndrome
  • hyperglycemic syndrome
  • hyperkalemia
  • back pain
  • symptomatic hypoglycemia
  • hypersensitivity reactions
  • acute pancreatitis
  • vesicular pemphigoid
  • rash
  • urticaria
  • gastritis
  • gastroesophageal reflux
  • gastrointestinal disorder unspecified
  • gastroenteritis
  • shortness of breath
  • bronchitis
  • sinusitis
  • chest pain
  • leg edema
  • arthritis
  • conjunctivitis
  • iron deficiency anemia
  • soft tissue infection
  • onychomycosis
  • abdominal pain
  • gastroesophageal reflux
  • cough
  • increased ALT
  • increased AST
  • fatigue
  • chest pain
  • leg pain
  • influenza-like illness
  • weight gain
  • motion sickness
  • ear disorder unspecified
  • tinnitus
  • glaucoma
  • allergic conjunctivitis
  • loss of appetite
  • anemia
  • folate deficiency
  • iron deficiency anemia
  • angina pectoris
  • palpitations
  • arrhythmia
  • exacerbation of hypertension
  • increased blood pressure
  • insomnia
  • intracranial hemorrhage
  • contusion
  • thyroiditis
  • leukocytosis
  • benign prostatic hyperplasia
  • irregular menstruation
  • laceration
  • hypoglycemia
  • nausea
  • vomiting

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from air and moisture. It is advisable to maintain a storage temperature between 1 and 30 degrees Celsius to ensure the medication remains effective for a long time.

Appearance and packaging

Appearance

Brown oblong film-coated tablet

Package unit

30 tablets/bottle, 100 tablets/bottle, 56 tablets (14 tablets/PTP × 4)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.